JP2010516675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516675A5 JP2010516675A5 JP2009546389A JP2009546389A JP2010516675A5 JP 2010516675 A5 JP2010516675 A5 JP 2010516675A5 JP 2009546389 A JP2009546389 A JP 2009546389A JP 2009546389 A JP2009546389 A JP 2009546389A JP 2010516675 A5 JP2010516675 A5 JP 2010516675A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- antigen
- group
- antibody
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 11
- 102000038129 antigens Human genes 0.000 claims 11
- 108091007172 antigens Proteins 0.000 claims 11
- 102000004965 antibodies Human genes 0.000 claims 7
- 108090001123 antibodies Proteins 0.000 claims 7
- 230000001225 therapeutic Effects 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 5
- 125000000524 functional group Chemical group 0.000 claims 4
- 102100011842 CEACAM5 Human genes 0.000 claims 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 102100001537 CA9 Human genes 0.000 claims 2
- 102100004099 CD74 Human genes 0.000 claims 2
- 101710007476 CD74 Proteins 0.000 claims 2
- 101710043957 CEACAM1 Proteins 0.000 claims 2
- 102100011828 CEACAM1 Human genes 0.000 claims 2
- 101710043956 CEACAM5 Proteins 0.000 claims 2
- 101710043951 CEACAM8 Proteins 0.000 claims 2
- 102100011841 CEACAM8 Human genes 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000589516 Pseudomonas Species 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 102000006382 Ribonucleases Human genes 0.000 claims 2
- 108010083644 Ribonucleases Proteins 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 230000002458 infectious Effects 0.000 claims 2
- -1 platinum coordination complex Chemical class 0.000 claims 2
- WJMFXQBNYLYADA-UHFFFAOYSA-N 1-(3,4-dihydroxyphenyl)-6,7-dihydroxy-1,2-dihydronaphthalene-2,3-dicarboxylic acid Chemical compound C12=CC(O)=C(O)C=C2C=C(C(O)=O)C(C(=O)O)C1C1=CC=C(O)C(O)=C1 WJMFXQBNYLYADA-UHFFFAOYSA-N 0.000 claims 1
- BLMFNYXTSPNJSB-UHFFFAOYSA-N 1-chloro-4-[2-[3-(4-chlorophenyl)prop-1-en-2-ylsulfonyl]prop-2-enyl]benzene Chemical compound C1=CC(Cl)=CC=C1CC(=C)S(=O)(=O)C(=C)CC1=CC=C(Cl)C=C1 BLMFNYXTSPNJSB-UHFFFAOYSA-N 0.000 claims 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- 108010066676 Abrin Proteins 0.000 claims 1
- 201000004304 Addison's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 210000000941 Bile Anatomy 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims 1
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 101700020617 CD22 Proteins 0.000 claims 1
- 102100000189 CD22 Human genes 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 102100016530 CD37 Human genes 0.000 claims 1
- 101700044364 CD37 Proteins 0.000 claims 1
- 102100019451 CD80 Human genes 0.000 claims 1
- 101700080477 CD80 Proteins 0.000 claims 1
- 101710043954 CEACAM3 Proteins 0.000 claims 1
- 102100011836 CEACAM3 Human genes 0.000 claims 1
- 101710043948 CEACAM7 Proteins 0.000 claims 1
- 101700007352 CGA Proteins 0.000 claims 1
- 102100012993 CGB3 Human genes 0.000 claims 1
- 101710013878 CGB8 Proteins 0.000 claims 1
- 102100009368 CR2 Human genes 0.000 claims 1
- 101700020447 CR2 Proteins 0.000 claims 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 claims 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 claims 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- 102100010912 EPCAM Human genes 0.000 claims 1
- 108060002563 EPCAM Proteins 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 231100000655 Enterotoxin Toxicity 0.000 claims 1
- 231100000776 Exotoxin Toxicity 0.000 claims 1
- 101700053597 FCER2 Proteins 0.000 claims 1
- 102100014608 FCER2 Human genes 0.000 claims 1
- 101700010580 FLO11 Proteins 0.000 claims 1
- 102100008658 FN1 Human genes 0.000 claims 1
- 101700036477 FOLH1 Proteins 0.000 claims 1
- 102100008453 FOLH1 Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 102000006815 Folate receptors Human genes 0.000 claims 1
- 108020005243 Folate receptors Proteins 0.000 claims 1
- 229960000304 Folic Acid Drugs 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 claims 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 101710037668 HCG Proteins 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N Iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 101700058542 KLK3 Proteins 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 102100006037 MUC1 Human genes 0.000 claims 1
- 101700052761 MUC1 Proteins 0.000 claims 1
- 101700010570 MUC17 Proteins 0.000 claims 1
- 102100013951 MUC2 Human genes 0.000 claims 1
- 101700036633 MUC2 Proteins 0.000 claims 1
- 101700075415 MUC3A Proteins 0.000 claims 1
- 102100013952 MUC3A Human genes 0.000 claims 1
- 101700032853 MUC4 Proteins 0.000 claims 1
- 102100013929 MUC4 Human genes 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 229960004961 Mechlorethamine Drugs 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 102100002997 NPEPPS Human genes 0.000 claims 1
- 101710027788 NPEPPS Proteins 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- 102100012897 PGF Human genes 0.000 claims 1
- 101710014083 PGF Proteins 0.000 claims 1
- 101710025567 PSAT1 Proteins 0.000 claims 1
- 101700004495 PSG2 Proteins 0.000 claims 1
- 102100005499 PTPRC Human genes 0.000 claims 1
- 101700059076 PTPRC Proteins 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010034695 Pernicious anaemia Diseases 0.000 claims 1
- 235000009074 Phytolacca americana Nutrition 0.000 claims 1
- 241001275115 Phytolacca bogotensis Species 0.000 claims 1
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 1
- 208000005987 Polymyositis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 229960000553 Somatostatin Drugs 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 229940014598 TAC Drugs 0.000 claims 1
- 102100018484 TACSTD2 Human genes 0.000 claims 1
- 101710024898 TACSTD2 Proteins 0.000 claims 1
- 102100009538 TNFRSF8 Human genes 0.000 claims 1
- 101710040533 TNFRSF8 Proteins 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010043207 Temporal arteritis Diseases 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 206010043554 Thrombocytopenia Diseases 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N Triazene Chemical compound NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102100015249 VEGFA Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 241000863480 Vinca Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N [N-]=C=S Chemical compound [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 claims 1
- 229930013930 alkaloids Natural products 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 230000002491 angiogenic Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001772 anti-angiogenic Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000845 anti-microbial Effects 0.000 claims 1
- 230000002927 anti-mitotic Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 230000001588 bifunctional Effects 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 101700059128 bre-3 Proteins 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 201000001973 choreatic disease Diseases 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 150000002019 disulfides Chemical class 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 239000002095 exotoxin Substances 0.000 claims 1
- 230000037320 fibronectin Effects 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 230000002518 glial Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 230000003834 intracellular Effects 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000000926 neurological Effects 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 244000045947 parasites Species 0.000 claims 1
- 201000011152 pemphigus Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 230000000861 pro-apoptotic Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000000750 progressive Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
Claims (16)
- 複合体であって、
(a)1つ以上の治療薬部分の複製、または二官能性治療薬部分に化学選択的に連結可能であるか、若しくは治療薬部分と非共有的に複合化できる官能基を含み、且つ、デキストラン、ポリグルタミン酸、およびデンドリマーから成る群より選択される官能化ポリマーと、
(b)(i)1つまたは2つのHSGまたはDTPAハプテン分子を含有するペプチド、(ii)葉酸、(iii)ソマトスタチン、(iv)VIP、(v)ビオチン、(vi)アンチセンスオリゴヌクレオチド、および(vii)ADペプチドから成る群より選択され、ポリマー分子各々に1から10の認識構造部分が付着しているポリマー分子と、
を含む、複合体。 - 前記治療薬部分は、化学療法薬、ビンカアルカロイド、アントラサイクリン、エピポドフィロトキシン、タキサン、代謝拮抗剤、アルキル化剤、抗生物質、Cox−2阻害剤、抗有糸分裂剤、抗血管形成活性剤、アポトーシス促進剤、ドキソルビシン、メトトレキサート、タキソール、カンプトテシン、ナイトロジェンマスタード、スルホン酸アルキル、ニトロソウレア、トリアゼン、葉酸類似体、ピリミジン類似体、プリン類似体、白金配位複合体、ホルモン、毒素、リシン、アブリン、リボヌクレアーゼ(RNase)、DNase I、ブドウ球菌エンテロトキシン−A、ヤマゴボウ抗菌タンパク質、ゲロニン、ジフテリア毒素、緑膿菌外毒素、および緑膿菌内毒素から成る群より選択される、請求項1に記載の複合体。
- 前記官能基は、1つ以上のアセチレン(またはアジド)、ヒドラジド、シクロデキストリン、ビニルスルホン、マレイミド、チオール、ブロモアセトアミド、ヨードアセトアミド、イソチオシアネート、および活性カルボキシル基より選択される、請求項1に記載の複合体。
- 前記官能基はアセチレンまたはアジドであり、連結は、アジドまたはアセチレンで誘導体化された薬剤を用いて行われる、請求項3に記載の複合体。
- 前記官能基はシクロデキストリンであり、前記治療薬部分は、非共有ホスト―ゲスト複合化によって連結される、請求項3に記載の複合体。
- 前記認識部分は、DNL方法の「AD」ペプチドであり、前記DNLアセンブリは、前記ポリマーへの薬剤または治療薬部分の付着前または後のいずれかに行われる、請求項1に記載の複合体。
- 前記薬剤を前記ポリマーに連結するスペーサは、細胞内で開裂可能な結合を含有し、前記開裂可能な結合はヒドラゾン、カテプシン−B−開裂可能ペプチド、ジスルフィド、およびエステラーゼによって開裂可能なエステル結合から成る群より選択される、請求項1に記載の複合体。
- 前記認識部分は、二重または多特異性抗体のアームのうちの1つに特異的であり、前記抗体の1つ以上の他のアームは、ムリン化、キメラ化、霊長類化、ヒト化、またはヒト単クローン抗体に由来する疾病標的MAbであり、前記抗体は、無傷フラグメント(Fab、Fab′、F(ab)2、F(ab′)2)、またはサブフラグメント(一本鎖組成物)形態である、請求項1に記載の複合体。
- 前記多特異性MAbは、LL1、LL2、hA20、1F5、L243、RS7、PAM−4、MN−14、MN−15、Mu−9、L19、G250、J591、CC49、およびImmu31から成る群より選択される、1つ以上の抗体を含む、二重特異性および/または二価抗体組成物である、請求項8に記載の複合体。
- 前記Mabは、癌または悪性細胞、感染性生物、自己免疫疾病、心血管疾病、または神経疾病に関連する抗原または抗原のエピトープと反応する、請求項9に記載の複合体。
- 前記癌細胞は、造血性腫瘍、癌腫、肉腫、黒色腫、またはグリア腫瘍に由来する細胞である、請求項10に記載の複合体。
- 前記MAbは、B−細胞系統抗原、T−細胞抗原、骨髄系統抗原またはHLA−DR抗原に結合する、請求項9に記載の複合体。
- 前記感染性生物は、バクテリア、ウィルス、真菌、微生物、または寄生生物である、請求項10に記載の複合体。
- 前記自己免疫疾病は、免疫媒介性血小板減少、皮膚筋炎、シェーグレン症候群、多発性硬化症、シデナム舞踏病、重症筋無力症、全身性エリテマトーデス、ループス腎炎、リウマチ熱、関節リウマチ、多腺性症候群、水疱性類天疱瘡、糖尿病、ヘノッホ−シェーンライン紫斑病、レンサ球菌感染後の腎炎、結節性紅斑、高安動脈炎、アジソン病、関節リウマチ、サルコイドーシス、潰瘍性大腸炎、多型性紅斑、IgA腎症、結節性多発性動脈炎、強直性脊椎炎、グッドパスチュア症候群、閉塞性血栓血管炎、原発性胆汁性肝硬変、橋本甲状腺炎、甲状腺亢進、強皮症、慢性活動性肝炎、多発性筋炎/皮膚筋炎、胆汁過多、尋常性天疱瘡、ヴェグナー肉芽腫症、膜性腎症、筋萎縮性側索硬化症、脊髄癆、巨大細胞動脈炎/多筋痛、悪性貧血、急速進行性糸球体腎炎、線維化性肺胞炎、および若年性糖尿病から成る群より選択される、請求項10に記載の複合体。
- 前記疾病標的抗体は、CD74、CD22、上皮糖タンパク質−1、癌胎児性抗原(CEAまたはCD66e)、大腸特異的抗原−p、α−フェトプロテイン、CC49、前立腺特異的膜抗原、炭酸脱水酵素IX、HER−2/neu、EGFR(ErbB1)、ErbB2、ErbB3、ILGF、BrE3、CD19、CD20、CD21、CD23、CD33、CD45、CD74、CD80、VEGF、ED−Bフィブロネクチン、PlGF、他の腫瘍血管形成抗原、MUC1、MUC2、MUC3、MUC4、ガングリオシド、HCG、EGP−2、CD37、HLA−DR、CD30、Ia、A3、A33、Ep−CAM、KS−I、Le(y)、S100、PSA、テネイシン、葉酸受容体、トーマス−フリードリッヒ抗原、腫瘍壊死抗原、Ga733、IL−2、IL−6、T101、MAGE、遊走阻止因子(MIF)、L243によって結合される抗原、PAM4によって結合される抗原、CD66a(BGP)、CD66b(CGM6)、66CDc(NCA)、66CDd(CGM1)、TACおよびそれらの組み合わせから成る群より選択される抗原に結合する、請求項10に記載の複合体。
- 前記抗体は、LL1、LL2、RFB4、hA20、1F5、L243、RS7、PAM−4、MN−14、MN−15、Mu−9、AFP−31、L19、G250、J591、CC49、L243、PAM4およびImmu31から成る群より選択される、請求項8に記載の複合体。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88532507P | 2007-01-17 | 2007-01-17 | |
PCT/US2007/088308 WO2008088658A2 (en) | 2007-01-17 | 2007-12-20 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014077058A Division JP2014159441A (ja) | 2007-01-17 | 2014-04-03 | 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010516675A JP2010516675A (ja) | 2010-05-20 |
JP2010516675A5 true JP2010516675A5 (ja) | 2011-02-10 |
Family
ID=39617967
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009546389A Pending JP2010516675A (ja) | 2007-01-17 | 2007-12-20 | 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分 |
JP2014077058A Pending JP2014159441A (ja) | 2007-01-17 | 2014-04-03 | 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014077058A Pending JP2014159441A (ja) | 2007-01-17 | 2014-04-03 | 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080171067A1 (ja) |
EP (1) | EP2121030A4 (ja) |
JP (2) | JP2010516675A (ja) |
AU (1) | AU2007343610C1 (ja) |
CA (2) | CA2675014C (ja) |
WO (1) | WO2008088658A2 (ja) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US8821868B2 (en) | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US9599619B2 (en) | 2002-06-14 | 2017-03-21 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
AU2005287375B8 (en) * | 2004-08-25 | 2009-11-12 | The Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
US8067006B2 (en) * | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
US8821899B2 (en) * | 2007-03-12 | 2014-09-02 | Board Of Regents, The University Of Texas System | Method and process for the production of multi-coated recognitive and releasing systems |
US8741316B2 (en) * | 2007-03-12 | 2014-06-03 | Board Of Regents, The University Of Texas System | Highly porous, recognitive polymer systems |
US8771713B2 (en) * | 2007-03-12 | 2014-07-08 | Board Of Regents, The University Of Texas System | Method and process for the production of multi-coated recognitive and releasing systems |
WO2008112826A1 (en) * | 2007-03-12 | 2008-09-18 | Board Of Regents, The University Of Texas System | Method and process for the production of multi-coated recognitive and releasing systems |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
CN108864285A (zh) | 2008-01-03 | 2018-11-23 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
WO2009151687A2 (en) | 2008-03-12 | 2009-12-17 | The Regents Of The University Of Michigan | Dendrimer conjugates |
US8034396B2 (en) * | 2008-04-01 | 2011-10-11 | Tyco Healthcare Group Lp | Bioadhesive composition formed using click chemistry |
KR101661636B1 (ko) | 2008-05-13 | 2016-09-30 | 유니버시티 오브 워싱톤 | 세포로의 전달을 위한 이블록 공중합체 및 그의 폴리뉴클레오티드 복합체 |
JP5755563B2 (ja) | 2008-05-13 | 2015-07-29 | ユニヴァーシティ オブ ワシントン | ミセル集合体 |
WO2009140421A2 (en) * | 2008-05-13 | 2009-11-19 | University Of Washington | Polymeric carrier |
WO2011091113A2 (en) | 2010-01-22 | 2011-07-28 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
CN102137681B (zh) * | 2008-08-08 | 2014-12-03 | 埃姆诺医药有限公司 | 抗胰腺癌抗体 |
CA2734917A1 (en) | 2008-08-22 | 2010-02-25 | University Of Washington | Heterogeneous polymeric micelles for intracellular delivery |
US8889635B2 (en) | 2008-09-30 | 2014-11-18 | The Regents Of The University Of Michigan | Dendrimer conjugates |
US8822213B2 (en) | 2008-11-06 | 2014-09-02 | University Of Washington | Bispecific intracellular delivery vehicles |
AU2009313358B2 (en) | 2008-11-06 | 2013-06-06 | Phaserx, Inc. | Multiblock copolymers |
US9017644B2 (en) | 2008-11-07 | 2015-04-28 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
CA2745926A1 (en) | 2008-12-08 | 2010-07-08 | Phaserx, Inc. | Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization |
US20100158850A1 (en) * | 2008-12-23 | 2010-06-24 | The Regents Of The University Of Michigan | Dendrimer based modular platforms |
CZ303072B6 (cs) * | 2009-02-13 | 2012-03-21 | Zentiva, K.S. | Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika |
PL3903829T3 (pl) * | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
US9523159B2 (en) | 2009-02-21 | 2016-12-20 | Covidien Lp | Crosslinked fibers and method of making same using UV radiation |
US8535477B2 (en) | 2009-02-21 | 2013-09-17 | Sofradim Production | Medical devices incorporating functional adhesives |
WO2010095049A1 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Crosslinked fibers and method of making same by extrusion |
WO2010095056A2 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Medical devices with an activated coating |
US8512728B2 (en) | 2009-02-21 | 2013-08-20 | Sofradim Production | Method of forming a medical device on biological tissue |
CA2753162A1 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Amphiphilic compounds and self-assembling compositions made therefrom |
WO2010096654A1 (en) | 2009-02-21 | 2010-08-26 | Tyco Healthcare Group Lp | Medical devices having activated surfaces |
US9555154B2 (en) | 2009-02-21 | 2017-01-31 | Covidien Lp | Medical devices having activated surfaces |
US8968733B2 (en) * | 2009-02-21 | 2015-03-03 | Sofradim Production | Functionalized surgical adhesives |
CA2753217A1 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices |
US8877170B2 (en) * | 2009-02-21 | 2014-11-04 | Sofradim Production | Medical device with inflammatory response-reducing coating |
WO2010095052A2 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Compounds and medical devices activated with solvophobic linkers |
US8663689B2 (en) * | 2009-02-21 | 2014-03-04 | Sofradim Production | Functionalized adhesive medical gel |
AU2010215200A1 (en) | 2009-02-21 | 2011-10-13 | Sofradim Production | Apparatus and method of reaching polymers by exposure to UV radiation to produce injectable medical devices |
US20120077774A1 (en) * | 2009-05-28 | 2012-03-29 | Cornell University | Compositions and their use for removing cholesterol |
US20120130045A1 (en) * | 2009-06-01 | 2012-05-24 | Ablitech, Inc. | Biomolecule-polymer conjugates and methods of making same |
BR112012004274A2 (pt) * | 2009-08-31 | 2016-11-16 | Ibc Pharmaceuticals Inc | composições e métodos de uso de imunotoxinas compreendendo ranpirnase (rap) mostram potente atividade citotóxica |
EP2488172A4 (en) | 2009-10-13 | 2014-08-13 | Univ Michigan | DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS |
WO2011059586A2 (en) | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Multifunctional small molecules |
WO2011062965A2 (en) | 2009-11-18 | 2011-05-26 | University Of Washington Through Its Center For Commercialization | Targeting monomers and polymers having targeting blocks |
CA2794336A1 (en) | 2010-03-25 | 2011-09-29 | Sofradim Production | Surgical fasteners and methods for sealing wounds |
CA2794335A1 (en) | 2010-03-25 | 2011-09-29 | Sofradim Production | Medical devices incorporating functional adhesives |
CA2804263A1 (en) | 2010-06-29 | 2012-01-12 | Tyco Healthcare Group Lp | Microwave-powered reactor and method for in situ forming implants |
EP2588153A2 (en) | 2010-07-01 | 2013-05-08 | Sofradim Production | Medical device with predefined activated cellular integration |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
EP2598178B1 (en) | 2010-07-27 | 2018-07-11 | Sofradim Production | Polymeric fibers having tissue reactive members |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EP2635300A4 (en) * | 2010-11-03 | 2014-04-02 | Ibc Pharmaceuticals Inc | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) |
ES2605990T3 (es) * | 2010-12-29 | 2017-03-17 | F. Hoffmann-La Roche Ag | Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos |
MX341118B (es) * | 2010-12-29 | 2016-08-09 | Arrowhead Res Corp | Cojugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima. |
CA2827076A1 (en) | 2011-02-15 | 2012-08-23 | Immumomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
CN102552930B (zh) * | 2011-10-28 | 2013-09-04 | 苏州大学 | 一种具有细胞靶向作用的水溶性紫杉醇衍生物及其制备 |
WO2013085718A1 (en) | 2011-12-08 | 2013-06-13 | The Regents Of The University Of Michigan | Multifunctional small molecules |
AU2014224049B2 (en) | 2013-02-28 | 2018-11-29 | Therabiol, Inc. | HIV antigens and antibodies |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
US9452228B2 (en) | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
US9775928B2 (en) | 2013-06-18 | 2017-10-03 | Covidien Lp | Adhesive barbed filament |
EP3027221A1 (en) | 2013-07-30 | 2016-06-08 | PhaseRx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
AU2016209295B2 (en) | 2015-01-21 | 2021-08-12 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
WO2017083604A1 (en) * | 2015-11-12 | 2017-05-18 | Amgen Inc. | Triazine mediated pharmacokinetic enhancement of therapeutics |
US11684584B2 (en) | 2016-12-30 | 2023-06-27 | Genevant Sciences Gmbh | Branched peg molecules and related compositions and methods |
CN107141323B (zh) * | 2017-06-26 | 2019-10-29 | 苏州大学 | 还原/pH双重响应性阿霉素前药及其制备方法与应用 |
US20230210998A1 (en) * | 2021-12-30 | 2023-07-06 | Navidea Biopharmaceuticals, Inc. | Methods for the conjugation of anthracyclines to carbohydrate polymeric carriers |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1541435A (en) * | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
NL8501219A (nl) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | Immunologisch complex, de bereiding en toepassing daarvan. |
US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US5770198A (en) * | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
JPH06172189A (ja) * | 1992-08-17 | 1994-06-21 | Bristol Myers Squibb Co | 胃腸保護複合剤 |
US5686578A (en) * | 1994-08-05 | 1997-11-11 | Immunomedics, Inc. | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
US20030198956A1 (en) * | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
US20040018587A1 (en) * | 1994-10-13 | 2004-01-29 | Lee Makowski | Nanostructures containing antibody assembly units |
US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
US7060506B2 (en) * | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
JP2005501052A (ja) * | 2001-07-31 | 2005-01-13 | イムノメディクス, インコーポレイテッド | ポリマー送達系 |
US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
US7011816B2 (en) * | 2001-12-26 | 2006-03-14 | Immunomedics, Inc. | Labeling targeting agents with gallium-68 and gallium-67 |
EP2295468B1 (en) * | 2002-02-14 | 2015-07-08 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
AU2003228809A1 (en) * | 2002-05-03 | 2003-11-17 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
EP1539941A4 (en) * | 2002-08-27 | 2006-11-29 | ADZYMES AND THEIR USES | |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
AU2002953073A0 (en) * | 2002-11-21 | 2003-01-16 | Access Pharmaceuticals Australia Pty Limited | Amplification of biotin-mediated targeting |
BR0317742A (pt) * | 2002-12-26 | 2005-11-22 | Mountain View Pharmaceuticals | Conjugados poliméricos de interferon-beta com potência biológica aumentada |
WO2004094613A2 (en) * | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
CA2783275A1 (en) * | 2003-07-24 | 2005-02-03 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for their preparation |
WO2006107617A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
JP4693355B2 (ja) * | 2004-03-01 | 2011-06-01 | 独立行政法人科学技術振興機構 | 核酸の光切断用組成物 |
US7608425B2 (en) * | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
AU2005287375B8 (en) * | 2004-08-25 | 2009-11-12 | The Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
AU2005294214A1 (en) * | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
AU2006218454B2 (en) * | 2005-03-03 | 2011-11-17 | Immunomedics, Inc. | Humanized L243 antibodies |
AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
-
2007
- 2007-12-20 CA CA2675014A patent/CA2675014C/en not_active Expired - Fee Related
- 2007-12-20 EP EP07869623.4A patent/EP2121030A4/en not_active Withdrawn
- 2007-12-20 US US11/961,436 patent/US20080171067A1/en not_active Abandoned
- 2007-12-20 JP JP2009546389A patent/JP2010516675A/ja active Pending
- 2007-12-20 WO PCT/US2007/088308 patent/WO2008088658A2/en active Application Filing
- 2007-12-20 CA CA2916671A patent/CA2916671C/en not_active Expired - Fee Related
- 2007-12-20 AU AU2007343610A patent/AU2007343610C1/en not_active Ceased
-
2014
- 2014-04-03 JP JP2014077058A patent/JP2014159441A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010516675A5 (ja) | ||
US11066468B2 (en) | Immunoconjugates with an intracellularly-cleavable linkage | |
AU2007343610C1 (en) | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | |
US8877901B2 (en) | Camptothecin-binding moiety conjugates | |
CA2713933C (en) | Camptothecin-binding moiety conjugates | |
JP2006511526A5 (ja) | ||
CN107469089B (zh) | 一种peg连接子及配基药物偶联物 | |
WO2023000131A1 (zh) | 一种负载双毒素的抗体药物偶联物及其应用 | |
JP2006514627A5 (ja) |